Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
28,281,317
-
Share change
-
+372,525
-
Total reported value
-
$414,830,000
-
Price per share
-
$14.69
-
Number of holders
-
52
-
Value change
-
+$5,453,146
-
Number of buys
-
24
-
Number of sells
-
12
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q3 2021
As of 30 Sep 2021,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,281,317 shares.
The largest 10 holders included
Cormorant Asset Management, LP, Logos Global Management LP, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., EcoR1 Capital, LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, BlackRock Inc., and VANGUARD GROUP INC.
This page lists
52
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.